oNKo-innate Pty Ltd

In our next few posts, we’ll explore some of the drugs the FDA approved in 2024 that alter the signalling of cytokines or growth factors. First up is 𝙣𝙤𝙜𝙖𝙥𝙚𝙣𝙙𝙚𝙠𝙞𝙣 𝙖𝙡𝙛𝙖 𝙞𝙣𝙗𝙖𝙠𝙞𝙘𝙚𝙥𝙩-𝙥𝙢𝙡𝙣 (𝘼𝙣𝙠𝙩𝙞𝙫𝙖) Developed by ImmunityBio, Inc. for the treatment of non-muscle invasive bladder cancer (NMIBC), Anktiva modulates the signaling of IL-15, one of our favourite cytokines. By activating the IL-15 receptor expressed on the surface of T cells and NK cells, Anktiva causes these cells to proliferate and activate, helping them fight tumors. Anktiva is used in combination with a vaccine known as Bacillus Calmette-Guérin (BCG), which is a front-line therapy for NMIBC. This is the first IL-15 therapy to be approved by the FDA, so it represents a significant step forward in the field of cytokine therapy for cancer. Read more at the links in the comments section below, and stay tuned for more in this series! #cytokinetherapy #anktiva #bladdercancer #IL15 #interleukin15 #immunotherapy #immunooncology https://lnkd.in/geVa_ZcK

𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗵𝗶𝗹𝗱𝗵𝗼𝗼𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗗𝗮𝘆 𝟮𝟬𝟮𝟱 Tomorrow, February 15th, is #internationalchildhoodcancerawarenessday Every 3 minutes, a child dies of cancer. This year, help contribute to Childhood Cancer International’s goal of providing better access to care for children and adolescents across the globe. Get involved and donate here! 👇https://lnkd.in/ei9rHG8u #ThroughTheirHands #ICCD2023 #cureall

Exciting opportunity to join oNKo-innate! We're #hiring a Scientist (Level I-II) in our Protein Engineering & Biotherapeutics team! Apply today or share this post with your network. Applications close 5/3/2025 https://lnkd.in/eMjaU5f7

Cytokine biology can be harnessed to great effectiveness in treating advanced cancer. A new #natureimmunology preclinical paper highlighting this below. The problem has always been maximizing the proinflammatory cytokine activity specifically in the tumor microenvironment & draining nodes, while abrogating the proinflammatory cytokine activity in healthy peripheral tissues & blood, thus obtaining a large therapeutic window for dose-escalation in cancer patients. oNKo-innate Pty Ltd have addressed this problem with oNKo-044, a cis-acting, potency optimized multispecific biologic (Ab-IL-12v-Fc) which has the desired activity only in the tumor microenvironment, not the periphery. The result, no systemic toxicity is observed throughout the broad efficacious dose range. A safe, systemically administered, IL-12-based immunotherapy agent with potent activity in the most difficult to treat PD1-refractory tumor models. Stay tuned for updates on oNKo-044's clinical development.   https://lnkd.in/gZUTBaB4

Introducing 𝘊𝘩𝘦𝘮𝘮𝘶𝘯𝘪𝘵𝘺: a discovery platform that harnesses the power of phenotypic screening with molecular glues to manipulate immune biology. 🧪 Read about molecular glues and how they work, our screening technology stack, and how the 𝘊𝘩𝘦𝘮𝘮𝘶𝘯𝘪𝘵𝘺 platform allows us to drug previously ‘undruggable’ targets in our latest article! 📜 https://lnkd.in/gijSkFAX #phenotypicscreening #molecularglue #targetedproteindegradation #immunology #chemmunity #drugdiscovery  

At oNKo-innate, interleukin-12 (IL-12) is one of our favourite cytokines. Why? Because it packs a powerful punch in the treatment of solid tumors.   In this article, we’re shining a much-deserved spotlight on IL-12 🔦 Join us as we explore the functions of IL-12, what makes IL-12 such a promising candidate in cancer immunotherapy, the obstacles that have prevented its clinical translation thus far, and what we’re doing differently at oNKo to make sure IL-12 cytokine therapy is safe and effective.     https://lnkd.in/gEQ9hqDx   #interleukin12 #IL12 #cancer #immunooncology #immunotherapy #cytokinetherapy 

It’s been another big year here at oNKo-innate, discovering new immuno-oncology targets and driving our therapeutic candidates toward the clinic. A big thanks to our amazing team, collaborators, advisory board, and everyone involved in the journey. With each year, we inch closer to a future without cancer. Happy holidays, everyone! #cancer #cancerresearch #immunooncology #australianbiotech #cytokinetherapy #immunotherapy

At oNKo-innate, interleukin-12 (IL-12) is one of our favourite cytokines. Why? Because it packs a powerful punch in the treatment of solid tumors.   In this article, we’re shining a much-deserved spotlight on IL-12 🔦 Join us as we explore the functions of IL-12, what makes IL-12 such a promising candidate in cancer immunotherapy, the obstacles that have prevented its clinical translation thus far, and what we’re doing differently at oNKo to make sure IL-12 cytokine therapy is safe and effective.     https://lnkd.in/gEQ9hqDx   #interleukin12 #IL12 #cancer #immunooncology #immunotherapy #cytokinetherapy 

Want to join a fast-paced and high performing biotechnology team? We're #hiring a new Manager, Laboratory Operations in Melbourne, Victoria. Apply today or share this post with your network. https://lnkd.in/gtY57fKB Applications close 22/12/2024

Our CSO, Nicholas Huntington, shares his expert perspective on a recent Nature publication involving IL-15 armored CAR-T cell therapy: “From my 20+ years working on IL-15 biology, I believe safe IL-15R agonism could be the key to unlocking CARs in solid tumors. Low and steady IL-15R signaling in CD8 T cells, NK cells, & γδ T cells promotes their metabolism. IL-15 co-expression induced lower glycolytic and higher oxidative phosphorylation, survival, proliferation, and effector functions. The observed disease control rate of 66% and antitumor response rate of 33% in this study is very encouraging for solid tumor CAR T cells! There was some increased severity of CRS seen with the IL-15-CARs but this is not surprising and can be addressed. There are numerous alternative approaches to exploit this IL-15 biology in a safer manner, including making the CAR T cells intrinsically more sensitive to endogenous IL-15 via gene edits. Several biotechs are using CISH deletion in their products to achieve the same...and CISH deletion is just the start. This is exciting progress for the patients, clinicians, and drug developers.” AstraZeneca Kite Pharma Bristol Myers Squibb Novartis Johnson & Johnson Roche #immunooncology #CARTcelltherapy #interleukin15 #cancer #cancerresearch https://lnkd.in/guneeike